Accretion Pharmaceuticals Limited — PPTs, 15-05-2026: Investor Presentation

Accretion Pharma showed strong FY26 performance. Revenue jumped 56.21% YoY to ₹89.6 crore, with Profit After Tax up 42.30% YoY to ₹9.7 crore. Growth was fueled by higher volumes and an improved product mix, especially in Oral Liquids and Tablets. EBITDA for the year stood at ₹15.0 crore with a 16.7% margin, and RoCE was 20.8%.

The company plans strategic expansion by diversifying geographically, moving to direct exports in Africa, Southeast Asia, and Latin America. Key strategies include new product development across segments and modernizing its Ahmedabad plant for efficiency. They are focused on adding new customers and increasing wallet share with existing ones.

Recent achievements include listing on NSE SME in May 2025 and receiving cGMP approvals from Malawi & Nigeria. Management expects continued robust demand from export markets, aiming for improved profitability as investments in product registrations yield results and operating leverage increases. They are focused on boosting capacity utilization and strengthening global partnerships.